COMPASS THERAPEUTICS INC (CMPX) Stock Price & Overview
NASDAQ:CMPX • US20454B1044
Current stock price
The current stock price of CMPX is 5.49 USD. Today CMPX is up by 3%. In the past month the price decreased by -6.79%. In the past year, price increased by 175.88%.
CMPX Key Statistics
- Market Cap
- 988.694M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.43
- Dividend Yield
- N/A
CMPX Stock Performance
CMPX Stock Chart
CMPX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to CMPX. When comparing the yearly performance of all stocks, CMPX is one of the better performing stocks in the market, outperforming 96.39% of all stocks.
CMPX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CMPX. While CMPX has a great health rating, there are worries on its profitability.
CMPX Earnings
CMPX Forecast & Estimates
21 analysts have analysed CMPX and the average price target is 14.37 USD. This implies a price increase of 161.8% is expected in the next year compared to the current price of 5.49.
CMPX Groups
Sector & Classification
CMPX Financial Highlights
Over the last trailing twelve months CMPX reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS decreased by -16.22% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.28% | ||
| ROE | -33.79% | ||
| Debt/Equity | 0 |
CMPX Ownership
CMPX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.96 | 362.828B | ||
| AMGN | AMGEN INC | 15.51 | 187.828B | ||
| GILD | GILEAD SCIENCES INC | 15.64 | 171.453B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.47 | 113.963B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 78.412B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.05 | 40.854B | ||
| INSM | INSMED INC | N/A | 29.992B | ||
| NTRA | NATERA INC | N/A | 27.569B | ||
| BIIB | BIOGEN INC | 11.77 | 26.995B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.13 | 23.31B | ||
| MRNA | MODERNA INC | N/A | 20.276B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.929B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CMPX
Company Profile
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Company Info
IPO: 2020-11-13
COMPASS THERAPEUTICS INC
80 Guest Street
Boston MASSACHUSETTS US
Employees: 35
Phone: 13026587581
COMPASS THERAPEUTICS INC / CMPX FAQ
What does CMPX do?
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2020-11-13. The firm is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Can you provide the latest stock price for COMPASS THERAPEUTICS INC?
The current stock price of CMPX is 5.49 USD. The price increased by 3% in the last trading session.
What is the dividend status of COMPASS THERAPEUTICS INC?
CMPX does not pay a dividend.
What is the ChartMill rating of COMPASS THERAPEUTICS INC stock?
CMPX has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about COMPASS THERAPEUTICS INC (CMPX) stock?
21 analysts have analysed CMPX and the average price target is 14.37 USD. This implies a price increase of 161.8% is expected in the next year compared to the current price of 5.49.
Can you provide the sector and industry classification for COMPASS THERAPEUTICS INC?
COMPASS THERAPEUTICS INC (CMPX) operates in the Health Care sector and the Biotechnology industry.
What is COMPASS THERAPEUTICS INC worth?
COMPASS THERAPEUTICS INC (CMPX) has a market capitalization of 988.69M USD. This makes CMPX a Small Cap stock.